Long/short equity, research analyst, biotech, healthcare

Short Vanda's Pending Catalyst For A 30% Gain

The bulls are sharpening their horns in sweet anticipation of Vanda Pharmaceuticals' (NASDAQ:VNDA) upcoming Advisory Committee Meeting with the FDA for tasimelteon's New Drug Application (NDA). Tasimelteon is a circadian regulator in development as an indication for Non-24Hr disorder in the totally blind.


Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
  • Access Top Ideas, chosen by Seeking Alpha’s editors
  • Filter long and short ideas by market cap and sector
  • Get Coverage of over 5,000 stocks, many of which have little or no coverage elsewhere
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO." Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else." Patrick Rice, Mainstay Capital Management
100% Satisfaction Guaranteed
You are protected by the Seeking Alpha Money Back Guarantee and will get a prompt refund on the unused portion of your subscription at any time, for any reason.